5-(3-dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-cyclopropylimidazole | 600639-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3-dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-cyclopropylimidazole
• 英文别名: 1-(2-cyclopropyl-3-propan-2-ylimidazol-4-yl)-3-(dimethylamino)prop-2-en-1-one
• CAS: 600639-00-7
• 化学式: C₁₄H₂₁N₃O
• 分子量: 247.34
• InChiKey: NIOCIHUREBMGLV-UHFFFAOYSA-N

物化性质

• 沸点：
  399.1±38.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.13
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  5-(3-dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-cyclopropylimidazole 、 碳酸胍 以 正丁醇 为溶剂， 生成 4-(2-cyclopropyl-3-isopropyl-3H-imidazol-4-yl)-pyrimidin-2-ylamine
  参考文献：
  名称：

  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was pro. led in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.075
• 作为产物：
  描述：

  1-(2-环丙基-3-异丙基-3H-咪唑-4-基)-乙酮 、 N,N-二甲基甲酰胺二甲基缩醛 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-(3-dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-cyclopropylimidazole
  参考文献：
  名称：

  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was pro. led in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.075

文献信息

• 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
  申请人：Andrews David

  公开号：US20090099160A1

  公开（公告）日：2009-04-16

  Compounds of the formula (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  化合物的公式（I）：其中变量基团如定义中所述，并描述了药物可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生细胞周期抑制（抗细胞增殖）作用的药物，用于温血动物，如人。
• Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders
  申请人：Andrews David

  公开号：US20080280906A1

  公开（公告）日：2008-11-13

  Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

  描述了具有细胞周期抑制活性的化合物，其化学式为（I）。
• Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
  申请人：AstraZeneca AB

  公开号：EP2301928A1

  公开（公告）日：2011-03-30

  Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

  式(I)化合物： 所述化合物具有细胞周期抑制活性。
• IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION
  申请人：AstraZeneca AB

  公开号：EP1869016A1

  公开（公告）日：2007-12-26
• [EN] IMIDAZ0L0-5-YL-2-ANIL0-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION<br/>[FR] IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES EN TANT QU'AGENTS D'INHIBITION DE LA PROLIFERATION CELLULAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2006095159A1

  公开（公告）日：2006-09-14

  [EN] Compounds of the formula (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.
  [FR] L'invention décrit des composés répondant à la formule (I) : dans laquelle les groupes variables sont tels que définis dans le mémoire descriptif, des sels acceptables sur le plan pharmaceutique et des esters hydrolysables in vivo. L'invention décrit en outre des procédés destinés à leur préparation et leur utilisation en tant que médicaments, en particulier, en tant que médicaments destinés à produire un effet inhibiteur du cycle cellulaire (anti-prolifération des cellules) chez un animal à sang chaud tel que l'homme.